Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/172632
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Perales, Celia | - |
dc.contributor.author | Chen, Qian | - |
dc.contributor.author | Soria, Maria Eugenia | - |
dc.contributor.author | Gregori, Josep | - |
dc.contributor.author | Garcia Cehic, Damir | - |
dc.contributor.author | Nieto Aponte, Leonardo | - |
dc.contributor.author | Castells, Lluis | - |
dc.contributor.author | Imaz, Arkaitz | - |
dc.contributor.author | Llorens Revull, Meritxell | - |
dc.contributor.author | Domingo, Esteban | - |
dc.contributor.author | Buti, Maria | - |
dc.contributor.author | Esteban, Juan Ignacio | - |
dc.contributor.author | Rodríguez-Frías, Francisco | - |
dc.contributor.author | Quer, Josep | - |
dc.date.accessioned | 2020-12-09T19:08:18Z | - |
dc.date.available | 2020-12-09T19:08:18Z | - |
dc.date.issued | 2018-01-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/172632 | - |
dc.description.abstract | Background: Controversy is ongoing about whether a minority mutant present at frequencies below 15% may be clinically relevant and should be considered to guide treatment. Methods: Resistance-associated substitution (RAS) studies were performed in patients before and at failure of antiviral treatments using Next-generation hepatitis C virus (HCV) sequencing (NGS). Results: We have found two patients with genotype 1a infection having RAS in 3.5%-7.1% of the viral population at baseline that were selected during ledipasvir + sofosbuvir treatment. Coselection of RAS located in a region not directly affected by the antiviral treatment also occurred. This observation calls into question, the recommendations to guide RAS-based direct-acting antiviral (DAA) treatment only when RAS are present in > 15% of the sequences generated. Conclusion: Our results suggests that RAS study should include all three HCV DAA target proteins and minority mutants should be considered as clinically relevant. | - |
dc.format.extent | 4 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Dove Medical Press Ltd. | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.2147/IDR.S172226 | - |
dc.relation.ispartof | Infection and Drug Resistance, 2018, vol. 11, p. 2207-2210 | - |
dc.relation.uri | https://doi.org/10.2147/IDR.S172226 | - |
dc.rights | cc by-nc (c) Perales et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | - |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Hepatitis C | - |
dc.subject.classification | Medicaments antivírics | - |
dc.subject.other | Hepatitis C | - |
dc.subject.other | Antiviral agents | - |
dc.title | Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-12-02T16:26:59Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30519058 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PeralesC.pdf | 135.88 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License